(Q36545072)

14 August 2017

1 reference

title

An update and review of antiretroviral therapy (English)

1 reference

14 August 2017

anti-retroviral agent

0 references

author name string

Frank J Piacenti

series ordinal

1

1 reference

PubMed ID

16863488

14 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

14 August 2017

1 reference

14 August 2017

26

1 reference

14 August 2017

8

1 reference

14 August 2017

1111-1133

1 reference

HIV drug resistance acquired through superinfection

14 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Tenofovir disoproxil fumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Tolerability of enteric-coated didanosine capsules compared with didanosine tablets in adults with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Emtricitabine: an antiretroviral agent for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Emtricitabine (FTC) for the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Emtricitabine/tenofovir disoproxil fumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Abacavir plus lamivudine: a review of their combined use in the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Identification and Distribution of HIV Type 1 Genetic Diversity and Protease Inhibitor Resistance–Associated Mutations in Shanghai, P. R. China

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitors-experienced patients: implications for tipranavir use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

New anti-HIV protease inhibitors provide more treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Cross-resistance patterns among HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Atazanavir: new option for treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Enfuvirtide: A Novel Agent for the Treatment of HIV-1 Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Enfuvirtide (T-20): A Novel Human Immunodeficiency Virus Type 1 Fusion Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

Co-receptor antagonists as HIV-1 entry inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.8.1111

21 January 2018

Identifiers

DOI

10.1592/PHCO.26.8.1111

1 reference

release_gt7djmexqvbdpi5ny4vgcbq4ai

14 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gt7djmexqvbdpi5ny4vgcbq4ai

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

16863488

1 reference

PubMed ID

16863488